Every 10-Q that REGENERATIVE MEDICAL TECH (RMTG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RMTG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMTG filings page.
Regenerative Medical Technology Group Inc. (RMTG) reported sharp top-line growth but remains highly leveraged and unprofitable for the quarter ended June 30, 2026. Quarterly revenue rose to $4.0 million from $1.0 million, and six‑month revenue increased to $6.66 million from $2.35 million, driven entirely by Global Stem Cells Group. Gross profit for the first half reached $4.34 million, a 65.2% gross margin, and operating results swung to an income from operations of $795,760 versus a loss a year earlier.
Despite this, heavy financing costs produced a larger net loss. Six‑month net loss widened to $3.22 million from $2.20 million, as interest expense more than doubled to $4.14 million. The balance sheet is highly stressed: total assets were $5.85 million against total liabilities of $45.1 million, resulting in a stockholders’ deficit of $39.3 million and a working capital deficit of $40.3 million. Accrued interest reached $19.6 million, promissory and convertible notes totaled about $19.8 million in principal, and warrant- and conversion-related derivative liabilities were $3.24 million.
Management discloses an accumulated deficit of $79.5 million and states there is substantial doubt about the company’s ability to continue as a going concern without additional debt or equity financing. Cash increased to $1.32 million, supported by new borrowing, but multiple notes are in default and further convertible debt was issued after quarter‑end, adding to potential dilution and financial risk.
Regenerative Medical Technology Group Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $2.64M, up about 93% from the prior-year quarter, driven by higher training, product supplies, and patient procedure activity at Global Stem Cells Group.
Gross profit increased to $1.77M with a gross margin near 67%, and income from operations improved to $0.23M. However, heavy financing costs dominated results: interest expense was $2.19M, partly offset by a $1.08M non-cash gain from lower derivative liability, leading to a net loss of $0.88M or $0.07 per share.
Cash was $1.06M at quarter-end, while total liabilities reached $40.63M, including approximately $21.46M of promissory notes and $18.02M of accrued interest. The company reports a working capital deficit of about $36.64M and an accumulated deficit of $76.24M, and it states that these factors raise substantial doubt about its ability to continue as a going concern without additional financing.
Regenerative Medical Technology Group Inc. (RMTG) reports higher revenue but deepening losses for the nine months ended September 30, 2025. Revenue rose to $3,528,393 from $2,596,671, driven entirely by Global Stem Cells Group, with growth in training, product supplies, and patient procedures. Cost of revenue increased, but the company still generated gross profit of $2,031,283.
Operating expenses climbed to $2,592,171, and heavy interest and financing costs pushed total other expense to $5,858,678, resulting in a net loss of $6,419,566 versus $4,924,785 a year earlier. The balance sheet shows assets of $4,519,827 against total liabilities of $34,574,268 and a stockholders’ deficit of $30,054,441. The company discloses a working capital deficit of $15,762,714 and an accumulated deficit of $73,972,668 and states there is substantial doubt about its ability to continue as a going concern.